Please note: The information displayed on this page might be outdated.
Pipeline Therapeutics: Developer of regenerative therapies designed to promote functional recovery of neurological diseases. Pipeline Therapeutics is a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, including synaptogenesis, remyelination and axonal repair. The company's lead clinical program, PIPE-505, is currently enrolling patients in a phase 1/2a study to treat sensorineural hearing loss (SNHL) associated with speech-in-noise disability. The company also has a portfolio of programs addressing a range of neurological disorders, including development candidate PIPE-307 which is focused on remyelination to treat multiple sclerosis.
US - Pacific
Phase l or ll
Autoimmune, Central Nervous System
10578 Science Center Drive
San Diego, CA 92121
San Diego, CA 92121
Company Participants at Winter Private Company Showcase
Pipeline Therapeutics, President & CEO
Carmine joined Pipeline Therapeutics in October 2018 as President & CEO. His previous role was President & CEO of Avelas Biosciences. Before that he served as Senior Vice President, Business Development for COI Pharmaceuticals, where he helped co-found five new biotech companies. When he was Vice President of Corporate Development for Afraxis Holdings, Carmine led and executed a $187.5 million license agreement with Roche’s subsidiary, Genentech. Carmine was also co-founder and CEO of Afraxis, Inc., a spin-out company from Afraxis Holdings. Before that, Carmine was with Phenomix Corporation as the Senior Director of Business Development, and previously held positions of increasing responsibility at Anadys Pharmaceuticals and Johnson & Johnson Pharmaceutical Research and Development. Carmine received his MBA from the Johnson Graduate School of Management at Cornell University. He also holds an M.S. degree in Organic Chemistry from Duke University and a B.S. in Chemistry from Wake Forest University.